Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.

No or weakly significant differences in age, T stage, or ERBB2 status were found between complete and incomplete responses.

also in 1,387 other papers

TP53 Status and Survival When patients with metastatic disease at diagnosis were excluded from the analysis, most patients with a TP53 mutant tumor had favorable event-free survival, although with the current median follow-up (46 mo, range 3–103 mo), it did not reach statistical significance ( Figure 1 B, left graph; Table S1 ).

also in 111,027 other papers